# APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

> **NCT03053466** · PHASE1 · COMPLETED · sponsor: **Apollomics (Australia) Pty. Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Solid Tumor
- Microsatellite Instability
- Mismatch Repair Deficiency
- Cancer of Unknown Primary Site

## Interventions

- **DRUG:** APL-501

## Key facts

- **NCT ID:** NCT03053466
- **Lead sponsor:** Apollomics (Australia) Pty. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-27
- **Primary completion:** 2022-02-25
- **Final completion:** 2022-02-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053466, "APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03053466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*